AOMs linked to significant weight regain at eight weeks after drug discontinuation compared with control group.

HealthDay News — Patients with irritable bowel syndrome (IBS) with self-perceived gluten sensitivity react similarly to wheat, gluten, and sham challenges, according to a study published online July ...

US Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. signed off on the recommendation from an expert panel that recommended removing the mercury-based preservative from all influenza ...

HealthDay News — Reusable feminine hygiene products often contain per- and polyfluoroalkyl substances (PFAS), according to a study published online July 22 in Environmental Science & Technology ...

Following publication of advisories, reports of local anesthetic poisoning decreased, but reports of lidocaine poisoning and mortality increased.

HealthDay News — Moderate US Preventive Services Task Force (USPSTF) preeclampsia risk factors have little value for estimating the risk for preeclampsia, according to a study published online ...

SAP-001 is an investigational oral agent designed to reduce serum uric acid levels by targeting a distinct renal urate reabsorption transporter.

The approval was based on data from the randomized, double-blind, placebo-controlled phase 3b AVA-PED-301 trial.

Researchers say findings point to gaps in prenatal HIV detection; the majority of infants not treated for HIV infection after birth were Black.

The single-arm, open-label DR-OVP-002 study is currently evaluating Ovaprene in sexually active women aged 18 to 40 years who ...

AD109 is an investigational oral therapy that combines aroxybutynin, an antimuscarinic, with atomoxetine, a selective norepinephrine reuptake inhibitor.

No difference in mortality risk seen for GLP-1 RA and SGLT2i users; significantly lower risk seen for GLP-1 RA vs DPP4i users.